Navigation Links
Long-Term Safety and Efficacy Data on Promacta(TM) (Eltrombopag) Presented at American Society of Hematology Annual Meeting
Date:12/10/2007

t 333 days. At baseline, 63% of patients had evidence of bleeding (World Health Organization [WHO] Grade 1-4) and 44% had platelet counts less than or equal to 15,000/microliters. Seventeen patients had entered stage two of the study. Median platelet count was 143,500 microliters. Twenty-seven patients proceeded to long-term treatment with PROMACTA (maintenance stage), achieving median platelet counts of 104,000/microliters with only one patient (4%) showing evidence of bleeding (WHO Grade 2-4).

About PROMACTA

PROMACTA is an oral, non-peptide, thrombopoietin receptor agonist that has been shown in pre-clinical research and clinical trials to stimulate the proliferation and differentiation of megakaryocytes, the bone marrow cells that give rise to blood platelets, and thus can be considered a platelet growth factor.(9) The efficacy and safety profile will be further examined in ongoing clinical trials. PROMACTA was discovered as a result of research collaboration between GlaxoSmithKline and Ligand Pharmaceuticals. It is being developed by GlaxoSmithKline.

About GlaxoSmithKline

GlaxoSmithKline is one of the world's leading research-based pharmaceutical and healthcare companies. GlaxoSmithKline is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information visit http://www.gsk.com.

Notes to Editors

PROMACTA(TM) is the registered trade mark of the GlaxoSmithKline group of companies.

PROMACTA(TM) is the proposed registered trademark to be used in the United States.

The study was financially supported by GlaxoSmithKline. Dr. Bussel is an Advisory Board Member for GlaxoSmithKline and has received research grant support, lecture fees, and consulting fees from GlaxoSmithKline and reports equity ownership in GlaxoSmithKline.

Enquiries

US Media inquiries:

Jeff McLaughlin 919-
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
2. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
3. Sexual Function Affected by Stem Cell Transplant According to Long-Term Study
4. Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinsons Disease
5. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
6. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
7. Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
8. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
9. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
10. Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus
11. Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)...  Lazarus Effect, a medical device company focused ... facilitate removal of blood clots, announced today that ... issued a new patent (U.S. Patent Number 8,795,305) ... TM and ReCover TM devices. ... stent-retriever (stentriever) with an integrated, novel, cover-based protection ...
(Date:7/24/2014)... , July 24, 2014 Consolidated Net ... Business Highlights   , India Business grew ... by 9.33% to Rs. 4,886.70 Mn Rest of World ... Europe Formulations Business grew by 34.53% to Rs. 977.26 Mn ... , Glenmark Pharmaceuticals Limited, the research-led global ...
(Date:7/24/2014)... -- In any given hospital in the country at any ... one hospital-acquired infection, according to the Centers of Disease ... prove fatal. And as increased surveillance has shown that ... per year, infection control efforts have drifted to the ... stronger emphasis is being placed upon innovative and comprehensive ...
Breaking Medicine Technology:Lazarus Effect Receives Notice of Allowance for New US Patent Covering Core Protection Technology 2Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 2Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 3Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 4Employees, Equipment and the Environment: Top Infection Prevention Focuses in Hospitals 2Employees, Equipment and the Environment: Top Infection Prevention Focuses in Hospitals 3
...  Medtronic, Inc, one of the world,s largest medical device ... U.S. Department of Justice (DOJ), the Office of the ... Services, and four relators in a qui tam suit ... in the U.S., including pacemakers and implantable cardioverter defibrillators ...
... A three-drug combination treatment for the blood cancer multiple myeloma ... patients, according to a multi-center study led by Andrzej ... the multiple myeloma program at the University of Chicago Medical ... of the phase I-II study on Dec. 12, 2011, ...
Cached Medicine Technology:Settlement Announced in Medtronic Qui Tam Case 2Drug Combination Highly Effective for Newly Diagnosed Myeloma Patients, Study Finds 2Drug Combination Highly Effective for Newly Diagnosed Myeloma Patients, Study Finds 3
(Date:7/24/2014)... for head and neck cancer (HNC). Evidence suggests certain cancers ... of HNC in patients with DM has not been well ... common type of cancer. It accounts for about 6 percent ... cases and 350,000 cancer deaths worldwide each year. , The ... the risk of HNC in patients with DM. The authors ...
(Date:7/24/2014)... This year the Walk to End ... Jackson National Life, will be held on Saturday, September 20 ... Kids Fun Run at 7:50 am, the untimed 5k Run ... , “The Walk to End Alzheimer’s unites the entire community ... fight against this devastating disease, “stated Linda Mitchell, CEO and ...
(Date:7/24/2014)... two or more equally positive outcomes experience paradoxical ... activity in different regions of the brain, according ... research scholar at the Princeton Neuroscience Institute at ... people rated the desirability of more than 300 ... at images of paired products with different or ...
(Date:7/24/2014)... Memantine was initially developed by Merz to ... under the brand name Akatinol; it was later licensed to ... in the USA to Forest Labs as Namenda. Lundbeck reported ... In the US, Forest reported Namenda sales of USD 1.5 ... Australia and the European region has increased the competition from ...
(Date:7/24/2014)... at Carnegie Mellon University, working with high-throughput data ... National Laboratory, have devised a computational method to ... breast cells turn malignant and as they respond ... analyzing how genes interact with each other in ... today by the online journal PLOS Computational ...
Breaking Medicine News(10 mins):Health News:Alzheimer's Association Walk to End Alzheimer's Steps Off Saturday, September 20 in Denver 2Health News:Alzheimer's Association Walk to End Alzheimer's Steps Off Saturday, September 20 in Denver 3Health News:Brain's dynamic duel underlies win-win choices 2Health News:Brain's dynamic duel underlies win-win choices 3Health News:Memantine Discussed in New Comprehensive Patent Search Report by Ark Patent Intelligence Published at MarketPublishers.com 2Health News:Memantine Discussed in New Comprehensive Patent Search Report by Ark Patent Intelligence Published at MarketPublishers.com 3Health News:Gene changes in breast cancer cells pinpointed with new computational method 2Health News:Gene changes in breast cancer cells pinpointed with new computational method 3
... ... undergoing leg amputation and detect heart disease earlier if diagnosis and treatment ... legs) were given higher priority by the NHS and there was better ... and Wales, the majority of which are caused by PAD, but there ...
... - Breast cancer patients with early stage disease that has ... radiation after mastectomy, because of the low present-day risk of ... could one day change the course of treatment for thousands ... University of Texas M. D. Anderson Cancer. The research, ...
... ... Sayer looked around for a good, reliable manufacturer for her award-winning cloth diapers, she did ... manufacturing facility, she also discovered a great way for her company to support its community ... Calgary, Alberta, Canada (PRWEB) ...
... may be the culprits, researchers suggest, , FRIDAY, March 5 ... red meat is a risk factor for heart disease, but ... meat -- not unprocessed red meat -- that increases the ... "processed meat" refers to any meat preserved by smoking, curing ...
... ... ... , ... , , , , ...
... ... ... ... ...
Cached Medicine News:Health News:Arterial disease awareness cuts heart attacks and leg amputations, claim UK vascular surgeons 2Health News:Arterial disease awareness cuts heart attacks and leg amputations, claim UK vascular surgeons 3Health News:Most early-stage breast cancer patients may not need radiation after mastectomy 2Health News:Most early-stage breast cancer patients may not need radiation after mastectomy 3Health News:Ecobumz Diapers are Going Green While Investing in its Own Community and Employing Women Looking to Enter or Re-enter the Workplace 2Health News:Processed Meat May Harm the Heart 2Health News:Processed Meat May Harm the Heart 3Health News:Processed Meat May Harm the Heart 4Health News:Global AIDS Alliance: U.S. Must Meet Its Obligations to Family Planning 2Health News:Global AIDS Alliance: U.S. Must Meet Its Obligations to Family Planning 3Health News:Endo to Present at Cowen and Company 30th Annual Health Care Conference 2Health News:Endo to Present at Cowen and Company 30th Annual Health Care Conference 3
Jewelers Forceps, delicate, straight....
Forceps, pointed, short jaws, suitable for epilation....
Cilia Forceps, slanted jaws, gold plated....
Accurate implant size. Polyoxymethylene (POM)....
Medicine Products: